Role of toll-like receptor signalling in Aβ uptake and clearance

Brain

Volumn 129, Issue 11, 2006, Pages 3006-3019

  Tahara, Kazuki ^a   Kim, Hong Duck ^a   Jin, Jing Ji ^a   Maxwell, J Adam ^a   Li, Ling ^b   Fukuchi, Ken Ichiro ^a,c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Alzheimer's disease; Amyloid; Microglia; Toll like receptors; Transgenic mouse

Indexed keywords

AMYLOID BETA PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; MUTATION; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT; STAINING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENOTYPE; LIGANDS; MICE; MICROGLIA; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9;

EID: 33750576993     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl249     Document Type: Article

References (59)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
3. Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD. Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. J Neurosci Res 1996; 43: 190-202.
4. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003; 23: 2665-74.
5. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-9.
6. Brazil MI, Chung H, Maxfield FR. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J Biol Chem 2000; 275: 16941-7.
7. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44: 227-32.
8. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523-30.
9. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013-21.
10. Chen K, Iribarren P, Hu J, et al. Activation of toll-like receptor 2 on microglia promotes cell uptake of Alzheimer's disease-associated amyloid beta peptide. J Biol Chem 2006; 281: 3651-9.
11. Chu T, Tran T, Yang F, Beech W, Cole GM, Frautschy SA. Effect of chloroquine and leupeptin on intracellular accumulation of amyloid-beta (A beta) 1-42 peptide in a murine N9 microglial cell line. FEBS Lett 1998; 436: 439-44.
12. Cui YH, Le Y, Gong W, Proost P, Van DJ, Murphy WJ, et al. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J Immunol 2002a; 168: 434-42.
13. Cui YH, Le Y, Zhang X, Gong W, Abe K, Sun R, et al. Up-regulation of FPR2, a chemotactic receptor for amyloid beta 1-42 (A beta 42), in murine microglial cells by TNF alpha. Neurobiol Dis 2002b; 10: 366-77.
14. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-53.
15. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging 2001; 22: 1007-12.
16. Doyle SE, O'Connell RM, Miranda GA, Vaidya SA, Chow EK, Liu PT, et al. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med 2004; 199: 81-90.
17. Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, et al. The LPS receptor (CD14) links innate immunity with Alzheimer s disease. FASEB J 2004; 18: 2035.
18. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
19. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002; 111: 927-30.
20. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
21. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, et al. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 2004; 190: 245-53.
22. Iribarren P, Chen K, Hu J, Gong W, Cho EH, Lockett S, et al. CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein- coupled receptor mFPR2. FASEB J 2005; 19: 2032-4.
23. Ishii KJ, Coban C, Akira S. Manifold mechanisms of toll-like receptor-ligand recognition. J Clin Immunol 2005; 25: 511-21.
24. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994; 13: 45-53.
25. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004; 13: 159-70.
26. Jarrett JT, Lansbury PT Jr. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73: 1055-8.
27. Kim HD, Kong FK, Cao Y, Lewis TL, Kim H, Tang DC, et al. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 2004; 370: 218-23.
28. Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002; 41: 345-52.
29. Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci 2004; 24: 9838-46.
30. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
31. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005; 128: 1778-9.
32. Lotz M, Ebert S, Esselmann H, Iliev AI, Prinz M, Wiazewicz N, et al. Amyloid beta peptide 1-40 enhances the action of toll-like receptor-2 and -4 agonists but antagonizes toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem 2005; 94: 289-98.
33. Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, Karlsson S, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis 2005; 18: 134-42.
34. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990; 335: 1037.
35. McKimmie CS, Roy D, Forster T, Fazakerley JK. Innate immune response gene expression profiles of N9 microglia are pathogen-type specific. J Neuroimmunol 2006; 175: 128-41.
36. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 2005; 3: 36-46.
37. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 2005; 64: 743-53.
38. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52.
39. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173: 3916-24.
40. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 1996; 17: 553-65.
41. Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem 1997; 272: 29390-7.
42. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR 4 gene. Science 1998; 282: 2085-8.
43. Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 2003; 137: 32-41.
44. Savage MJ, Kawooya JK, Pinsker LR, Emmons TL, Mistretta SSR, Greenberg BD. Elevated A-beta levels in Alzheimer's disease brain are associated with selective accumulation of A-beta 42 in parenchymal amyloid plaques and both A-beta40 and A-beta42 in cerebrovascular deposits. Int J Exp Clin Invest 1995; 2: 234-40.
45. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
46. Schenk DB, Yednock T. The role of microglia in Alzheimer's disease: friend or foe? Neurobiol Aging 2002; 23: 677-9.
47. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 2003; 14: 133-45.
48. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-32.
49. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-69.
50. Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 2002; 5: 1288-93.
51. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120: 545-55.
52. Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett 2001; 307: 101-4.
53. Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR, et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol 2005; 35: 901-10.
54. Veld BA, Ruitenberg A, Launer LJ. Duration of nonsteroidal antiinflammatory drug use and risk of Alzheimer's disease. The Rotterdam study. Neurobiol Aging 2000; 21: S204.
55. Walker DG, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res 2005; 81: 412-25.
56. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9.
57. Wang SS, Becerra-Arteaga A, Good TA. Development of a novel diffusion-based method to estimate the size of the aggregated Abeta species responsible for neurotoxicity. Biotechnol Bioeng 2002; 80: 50-9.
58. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol 2000; 161: 127-38.
59. Woodroofe MN, Cuzner ML. Cohen J, Wilkin GP. Microglia: the tissue macrophage of the CNS. Neural cell culture: a practical approach. IRL Press (at Oxford University Press); 1995. p. 107-19.